Abstract
BackgroundCurrently available biomarkers are imperfect in their ability to predict responses to the multiple first-line treatment options available for patients with advanced non-small cell lung cancer (NSCLC). Having an early...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have